natgillin/translations-raw huggingface dataset:
Data from the long-term extension studies until 24 months revealed a renal safety profile consistent with that observed in the placebocontrolled studies. 
Podaci iz dugotrajnih nastavaka ispitivanja do 24 mjeseca pokazali su bubrežni sigurnosni profil dosljedan onom opaženom u placebom kontroliranim ispitivanjima.
• At the request of the European Medicines Agency; • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• Uoči svake izmjene sustava za upravljanje rizikom, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik, odnosno kada je omjer korist/rizik rezultat ostvarenja nekog važnog cilja (u smislu farmakovigilancije ili smanjenja rizika.
Following administration of a single oral dose of lesinurad in either the fed or fasted state, maximum plasma concentrations (Cmax) were attained within 1 to 4 hours. 
Nakon primjene jednokratne oralne doze lesinurada, bilo u stanju sitosti ili natašte, maksimalne koncentracije u plazmi (Cmax) postignute su unutar 1 do 4 sata.
In vitro assessment of interactions 
In vitro procjena interakcija
Mean plasma-to-blood ratios of lesinurad AUC and Cmax were approximately 1.8, indicating that radioactivity was largely contained in the plasma space and did not penetrate or partition extensively into red blood cells. 
Srednji omjeri AUC i Cmax lesinurada u plazmi u odnosu na krv bili su otprilike 1,8, što ukazuje da je radioaktivnost uvelike zadržana u plazmi i nije se opsežno proširila ili preraspodijelila u crvene krvne stanice.
However, individual values were well within the range observed in the extensive metaboliser subjects. 
Međutim, pojedine vrijednosti bile su dobrano unutar raspona opaženog u brzih metabolizatora.
*Photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria. 
*Fotodermatoza, reakcija fotoosjetljivosti, alergijski dermatitis, pruritus i urtikarija.
Based on in vitro data, lesinurad may be a mild inducer of CYP2B6 but this interaction has not been studied clinically. 
Na temelju in vitro podataka, lesinurad može biti blagi induktor CYP2B6, ali ova interakcija nije klinički ispitana.
Within 7 days following single dosing of radiolabelled lesinurad, 63% of administered radioactive dose was recovered in urine and 32% of administered radioactive dose was recovered in faeces. 
Unutar 7 dana nakon jednokratne doze radioaktivno obilježenog lesinurada, 63% primijenjene radioaktivne doze bilo je nađeno u mokraći, a 32% primijenjene radioaktivne doze bilo je nađeno u stolici.
By lowering the amount of uric acid in the blood, Zurampic stops this accumulation and may prevent further joint damage. 
Sniženjem količine mokraćne kiseline u krvi, Zurampic zaustavlja to nakupljanje i može spriječiti daljnje oštećenje zglobova.
You should avoid taking Zurampic during pregnancy or if you are breast-feeding. 
Trebate izbjegavati uzimanje lijeka Zurampic tijekom trudnoće ili dojenja.
Time from Baseline in Months 
Vrijeme od početka ispitivanja u mjesecima
URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. 
URAT1 je odgovoran za većinu ponovne apsorpcije filtrirane mokraćne kiseline iz lumena bubrežnih kanalića.
Zurampic may cause serious kidney problems (see section 4), which occur more frequently if Zurampic is taken alone (see section 3). 
Zurampic može uzrokovati ozbiljne probleme s bubrezima (vidjeti dio 4), koji mogu biti češći ako se Zurampic uzima sam (vidjeti dio 3).
injections, patches and implants - rifampin - to treat tuberculosis - warfarin - to prevent and treat blood clots forming in the legs, lungs, brain and heart. 
„pilule“), injekcije, naljepke (flastere) i implantate - rifampicin -za liječenje tuberkuloze - varfarin -za sprječavanje i liječenje nastanka krvnih ugrušaka u nogama, plućima, mozgu i srcu.
BLISTER NON-PERFORATED (10 TABLETS) BLISTER PERFORATED UNIT DOSE CALENDAR BLISTER (14 TABLETS) 
NEPERFORIRANI BLISTER (10 TABLETA) PERFORIRANI BLISTER S JEDINIČNIM DOZAMA KALENDARSKI BLISTER (14 TABLETA)
Children and adolescents Zurampic is not recommended for use in children and adolescents below 18 years of age. 
Ne preporučuje se primjena lijeka Zurampic u djece i adolescenata mlađih od 18 godina.
Do not use this medicine after the expiry date which is stated on the carton or blister foil after “EXP”. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji iza oznake „Rok valjanosti“ ili foliji blistera iza oznake „EXP“.
If you take more Zurampic than you should If you take more of this medicine than you should, talk to a doctor or go to the nearest hospital. 
Ako uzmete više ovog lijeka nego što ste trebali obavijestite svog liječnika ili otiđite u najbližu bolnicu.
Zurampic must never be taken without a ‘xanthine oxidase inhibitor' medicine. 
Zurampic se nikada ne smije uzeti bez inhibitora ksantin oksidaze.
Zurampic should be interrupted if serum creatinine is elevated to greater than 2 times the pre-treatment value or in case of an absolute serum creatinine value greater than 4.0 mg/dL. 
Primjenu lijeka Zurampic treba privremeno prekinuti ako razina serumskog kreatinina poraste više nego dvostruko u odnosu na vrijednost prije početka liječenja ili u slučaju apsolutne vrijednosti serumskog kreatinina veće od 4,0 mg/dl.
Based on interaction studies in healthy subjects or gout patients, Zurampic does not have clinically significant interactions with NSAIDs (naproxen and indomethacin), colchicine, repaglinide, tolbutamide, febuxostat or allopurinol. 
Temeljeno na ispitivanjima interakcija u zdravih ispitanika ili bolesnika s gihtom, Zurampic ne stupa u klinički značajne interakcije s NSAIL-ovima (naproksenom i indometacinom), kolhicinom, repaglinidom, tolbutaminom, febuksostatom ili alopurinolom.
Warnings and precautions Talk to your doctor or pharmacist before taking Zurampic. 
Upozorenja i mjere opreza Obratite se svom liječniku ili ljekarniku prije nego uzmete Zurampic.
- if you have ‘tumour lysis syndrome' - a fast breakdown of cancer cells which can cause high uric acid levels - if you have ‘Lesch-Nyhan syndrome' -a rare inherited illness that starts in childhood where there is too much uric acid in the blood - if your kidneys work very poorly or you have ‘End-Stage Kidney Disease' - if you have received a kidney transplant - if you are on kidney dialysis. 
- ako imate „sindrom lize tumora“ - brzi raspad stanica raka koji može uzrokovati visoke razine mokraćne kiseline - ako imate „Lesch-Nyhanovsindrom“-rijetku nasljednu bolest koja počinje u djetinjstvu kada postoji previše mokraćne kiseline u krvi - ako Vaši bubrezi rade jako slabo ili imate „završni stadij bolesti bubrega“ - ako Vam je transplantiran bubreg - ako ste na dijalizi bubrega
The recommended dose is 1 tablet of 200 mg once a day in the morning. 
Preporučena doza je 1 tableta od 200 mg jedanput dnevno ujutro.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Zurampic. 
Ako se bilo što od gore navedenog odnosi na Vas (ili ako niste sigurni), obratite se svom liječniku ili ljekarniku prije nego uzmete Zurampic.
Gout is a type of arthritis caused by an accumulation of urate crystals around the joints. 
Giht je vrsta artritisa uzrokovana nakupljanjem kristala urata u zglobovima.
Your doctor may give you other medicines such as ‘colchicine' and ‘nonsteroidal anti-inflammatory drugs (NSAIDs)'. 
Vaš liječnik Vam može dati druge lijekove, poput kolhicina ili nesteroidnih protuupalnih lijekova.
Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment. 
Vezanje na proteine u plazmi nije značajno promijenjeno u bolesnika s oštećenjem funkcije bubrega ili jetre.
Patients should be informed that failure to follow these instructions may increase the risk of renal events (see section 4.4). 
Bolesnike treba informirati da nepridržavanje ovih uputa može povećati rizik od bubrežnih događaja (vidjeti dio 4.4).
Patients known to be CYP2C9 poor metabolisers should be treated with caution, as the potential risk of renal-related adverse effects may be increased (see sections 4.8 and 5.2). 
Bolesnike za koje je poznato da su spori CYP2C9 metabolizatori treba liječiti s oprezom, jer mogući rizik od štetnih učinaka povezanih s bubrezima može biti povećan (vidjeti dijelove 4.8 i 5.2).
Lesinurad is a mild to moderate inducer of CYP3A and therefore may lower plasma concentrations of some hormonal contraceptives, thereby decreasing contraceptive effectiveness (see sections 4.4 and 
Lesinurad je blagi do umjereni induktor CYP3A i prema tome može sniziti koncentracije nekih hormonskih kontraceptiva u plazmi te time smanjiti učinkovitost kontracepcije (vidjeti dijelove 4.4 i
The lack of an observed interaction could be due to the combination of the induction of CYP2C9 and inhibition of OATP1B1 and 1B3. 
Izostanak zamijećene interakcije može biti posljedica kombinacije indukcije CYP2C9 i inhibicije OATP1B1 i 1B3.
Pack sizes of 10, 28, 30, 98 in non-perforated blisters. 
Veličine pakiranja od 10, 28, 30, 98 tableta u neperforiranim blisterima.
The effect of lesinurad on fertility in humans has not been studied. 
Nije ispitan učinak lesinurada na plodnost u ljudi.
Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Zurampic is co-administered. 
Hormonski kontraceptivi, uključujući oralne, injekcijske i transdermalne oblike te implantate, mogu biti nepouzdani kada se primjenjuju istodobno s lijekom Zurampic.
Available pharmacodynamic/toxicological data in rats have shown excretion of lesinurad in milk. 
Dostupni farmakodinamički/toksikološki podaci u štakora pokazali su da se lesinurad izlučuje u majčino mlijeko.
The safety of Zurampic 200 mg was evaluated in the Phase 3 combination therapy clinical trials (including extension studies). 
Sigurnost lijeka Zurampic u dozi od 200 mg procijenjena je u kliničkim ispitivanjima kombinirane terapije faze 3 (uključujući nastavke ispitivanja).
In patients with tophi or persistent symptoms, the target is less than 5 mg/dL (300 µmol/L). 
U bolesnika s tofima ili trajnim simptomima, ciljna razina je manje od 5 mg/dl (300 µmol/l).
Wait and take your next dose of Zurampic with your next morning dose of allopurinol or febuxostat. 
Pričekajte i uzmite Vašu sljedeću dozu lijeka Zurampic s Vašom sljedećom jutarnjom dozom alopurinola ili febuksostata.
Lesinurad is a mild to moderate inducer of CYP3A (see section 4.5). 
Lesinurad je blagi do umjereni induktor CYP3A (vidjeti dio 4.5).
Your doctor may tell you to restart treatment with Zurampic when your kidney function improves. 
Vaš liječnik Vam može reći da ponovno počnete uzimati Zurampic kada se poboljša funkcija Vaših bubrega.
Based on population pharmacokinetic analysis, age, gender, race and ethnicity do not have a clinically meaningful effect on the pharmacokinetics of lesinurad. 
S obzirom na analizu populacijske farmakokinetike, ne postoji klinički značajan utjecaj dobi, spola, rase ili etničke pripadnosti na farmakokinetiku lesinurada.
Zurampic has not been studied in patients with severe hepatic impairment; therefore, dose recommendations cannot be given. 
Zurampic nije ispitivan u bolesnika s teškim oštećenjem funkcije jetre; prema tome, ne mogu se dati preporuke za doziranje.
Epoxide hydrolase inhibitors 
Inhibitori epoksid hidrolaze
The possibility of reduced efficacy of concomitant medicinal products that are CYP3A substrates should be considered and their efficacy (e.g. blood pressure and cholesterol levels) should be monitored (see section 4.4). 
Treba uzeti u obzir mogućnost smanjene djelotvornosti istodobno primjenjivanih lijekova koji su supstrati CYP3A te je potrebno pratiti njihovu djelotvornost (npr. krvni tlak i razinu kolesterola) (vidjeti dio 4.4).
If you are not sure, talk to your doctor or pharmacist before taking Zurampic. 
Ako niste sigurni, obratite se svom liječniku ili ljekarniku prije nego uzmete Zurampic.
There is no clinical experience in patients with severe (Child-Pugh class C) hepatic impairment. 
Ne postoji kliničko iskustvo u bolesnika s teškim (Child-Pugh stadij C) oštećenjem funkcije jetre.
Renal function should be evaluated prior to initiation of Zurampic and monitored periodically thereafter, e.g. 4 times per year, based on clinical considerations, such as baseline renal function, volume depletion, concurrent illness or concomitant medications. 
Funkciju bubrega treba procijeniti prije početka primjene lijeka Zurampic, te je redovito pratiti tijekom liječenja, npr. 4 puta godišnje, na temelju kliničkih okolnosti poput početne funkcije bubrega, deplecije volumena, istodobno prisutne bolesti ili istodobno primjenjivanih lijekova.
Rifampin 
Rifampicin
Based on these studies, Zurampic is only recommended at a dose of 200 mg once daily in combination with a xanthine oxidase inhibitor (see sections 4.2 and 4.4). 
Temeljeno na ovim ispitivanjima, Zurampic se preporučuje samo u dozi od 200 mg jedanput dnevno u kombinaciji s inhibitorom ksantin oksidaze (vidjeti dijelove 4.2 i 4.4).
In an interaction study conducted in healthy subjects with multiple doses of Zurampic 400 mg and single dose warfarin (25 mg), lesinurad led to a decrease in exposure of R-warfarin (the less active enantiomer) and had no effect on the exposure of S-warfarin (the more active enantiomer). 
U ispitivanju interakcija provedenom na zdravim ispitanicima uz višestruke doze lijeka Zurampic od 400 mg i jednokratnu dozu varfarina (25 mg), lesinurad je doveo do smanjenja u izloženosti Rvarfarinu (manje aktivan enantiomer) i nije imao učinak na izloženost S-varfarinu (aktivniji enantiomer).
Rare - may affect up to 1 in 1000 people - skin reactions, including redness, itchy skin, lumpy rash (hives) and skin rash on exposure to sunshine. 
Rijetko - mogu se javiti u do 1 na 1000 osoba - kožne reakcije, uključujući crvenilo, svrbež kože, osip s uzdignućima na koži (koprivnjača) i osip na koži nakon izlaganja suncu.
Secondary hyperuricaemia 
Sekundarna hiperuricemija
Fluconazole, a moderate CYP2C9 inhibitor, increased lesinurad AUC (56%) and Cmax (38%), as well as the amount of lesinurad excreted unchanged in urine. 
Flukonazol, umjereni inhibitor CYP2C9, povećao je AUC (56%) i Cmax (38%) lesinurada, kao i količinu nepromijenjenog lesinurada izlučenog u mokraći.
Additional monitoring of lipids and blood pressure is recommended in patients using sensitive CYP3A substrate lipid lowering medicines (such as lovastatin or simvastatin) or antihypertensive medicines (such as amlodipine, felodipine or nisoldipine), since their efficacy may be reduced (see section 4.5). 
Preporučuje se dodatno praćenje lipida i krvnog tlaka u bolesnika koji uzimaju lijekove koji su osjetljivi supstrati CYP3A za sniženje lipida (poput lovastatina ili simvastatina) ili sniženje krvnog tlaka (poput amlodipina, felodipina ili nisoldipina), s obzirom da njihova djelotvornost može biti smanjena (vidjeti dio 4.5).
In interaction studies conducted in healthy subjects with Zurampic and CYP3A substrates, lesinurad reduced the plasma concentrations of sildenafil and amlodipine. 
U ispitivanjima interakcija provedenima na zdravim ispitanicima s lijekom Zurampic i supstratima CYP3A, lesinurad je smanjio koncentracije sildenafila i amlodipina u plazmi.
The recommended minimum dose of allopurinol is 300 mg, or 200 mg for patients with moderate renal impairment (creatinine clearance [CrCL] of 30-59 mL/min). 
Preporučena minimalna doza alopurinola je 300 mg, ili 200 mg za bolesnike s umjerenim oštećenjem funkcije bubrega (klirens kreatinina [CrCL] od 30 do 59 ml/min).
Experience with Zurampic in patients with an estimated CrCL (eCrCL) less than 45 mL/min is limited; therefore, Zurampic should be used with caution in patients with a CrCL from 30 mL/min to less than 45 mL/min. 
Iskustvo s lijekom Zurampic u bolesnika s procijenjenim CrCL-om (eCrCL) manjim od 45 ml/min je ograničeno; stoga se Zurampic mora primjenjivati s oprezom u bolesnika s CrCL od 30 ml/min do 45 ml/min.
You must use Zurampic together with either allopurinol or febuxostat. 
Zurampic morate uzimati zajedno s alopurinolom ili febuksostatom.
An induction effect of lesinurad should be anticipated after 2 to 3 weeks of continuous co-administration of Zurampic. 
Indukcijski učinak lesinurada treba se očekivati nakon 2 do 3 tjedna kontinuirane istodobne primjene s lijekom Zurampic.
- acetylsalicylic acid - to relieve fever and pain - at doses above 325 mg per day - medicines to treat high blood pressure, e.g. amlodipine - medicines to treat high cholesterol levels, e.g. simvastatin - fluconazole - to treat fungal infections - amiodarone -to treat heart rhythm problems - valproic acid,valpromideor carbamazepine -to treatfits (seizures), mood disorders and prevent migraines - sildenafil - to treat erectile dysfunction - contraceptives-used to preventpregnancy,including oralcontraception (such as ‘the pill'), 
- acetilsalicilatna kiselina -za ublažavanje vrućice i bolova -u dozama većim od 325 mg nadan - lijekovi za liječenje visokog krvnog tlaka, npr. amlodipin - lijekovi za liječenje visokih razina kolesterola, npr. simvastatin - flukonazol - za liječenje gljivičnih infekcija - amiodaron-za liječenje problema srčanog ritma - valproatna kiselina, valpromid ili karbamazepin -za liječenje napadaja i poremećaja raspoloženja te sprječavanje migrena - sildenafil -za liječenje erektilne disfunkcije - kontraceptivi-koriste se za sprječavanje trudnoće, uključujući oralnu kontracepciju (poput
Placebo + febuxostat 80 mg N=51 
Vremenska točka Placebo + febuksostat 80 mg N=51
System Organ Classification Common 
Klasifikacija organskih sustava
Effect of other medicinal products on lesinurad 
Učinci drugih lijekova na lesinurad
Oval, 5.7 x 12.9 mm, blue tablets. 
Ovalne tablete plave boje, dimenzija 5,7 x 12,9 mm.
All studies were of 12 months duration and patients received prophylaxis for gout flares with colchicine or NSAIDs during the first 5 months of lesinurad treatment. 
Sva ispitivanja trajala su 12 mjeseci i u bolesnika je primijenjeno profilaktičko liječenje akutnih napadaja gihta kolhicinom ili NSAIL-ovima tijekom prvih 5 mjeseci liječenja lesinuradom.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Ako Vam je Vaš liječnik rekao da ne podnosite neke šećere, obratite se svom liječniku prije nego uzmete ovaj lijek.
Uncommon - may affect up to 1 in 100 people - kidney stones, - dehydration (loss of too much fluid from your body). 
Manje često - mogu se javiti u do 1 na 100 osoba - bubrežni kamenci, - dehidracija (gubitak prevelike količine tekućine iz tijela).
Lesinurad at doses up to 1,600 mg did not demonstrate an effect on ECG parameters (including QTc interval) in healthy subjects. 
U zdravih ispitanika, lesinurad u dozama do 1600 mg nije pokazao učinak na EKG parametre (uključujući QTc interval).
The most commonly reported adverse reactions during treatment with Zurampic 200 mg are influenza, gastro-oesophageal reflux disease, headache and blood creatinine increased. 
Najčešće prijavljivane nuspojave tijekom liječenja lijekom Zurampic u dozi od 200 mg su gripa, gastroezofagealna refluksna bolest, glavobolja i povišen kreatinin u krvi.
For cardiovascular patients in a stable condition, the benefit/risk balance should be assessed for each individual patient on an ongoing basis, taking into account the benefits of lowering urate levels versus a potential increase in cardiac risk (see section 4.8). 
Za kardiovaskularne bolesnike čije je stanje stabilno, mora se redovito provoditi procjena omjera koristi i rizika za svakog pojedinog bolesnika, uzimajući u obzir koristi sniženja razine urata naspram mogućeg povećanja srčanih rizika (vidjeti dio 4.8).
Sixty-six percent of patients had mild or moderate renal impairment. 
Šezdeset i šest posto bolesnika imalo je blago ili umjereno oštećenje funkcije bubrega.
Failure to follow these instructions may increase the risk of kidney side effects (see section 4). 
Nepridržavanje ovih uputa može povećati rizik od nuspojava bubrega (vidjeti dio 4).
In addition, lesinurad is an in vitro inducer of CYP2B6 and CYP3A via CAR/PXR. 
Dodatno, lesinurad je in vitro induktor CYP2B6 i CYP3A preko CAR/PXR.
In clinical trials, most adverse reactions were mild or moderate in intensity and resolved while continuing Zurampic therapy. 
U kliničkim ispitivanjima, većina je nuspojava bila blagog do umjerenog intenziteta i razriješena je uz nastavak liječenja lijekom Zurampic.
If you stop taking your xanthine oxidase inhibitor medicine, you must also stop taking Zurampic. 
Ako prestanete uzimati lijek koji je inhibitor ksantin oksidaze, morate također prestati uzimati i Zurampic.
Fifty percent of patients had a baseline sUA ≥5.0 mg/dL, which was after 3 weeks of treatment with febuxostat alone. 
Pedeset posto bolesnika imalo je početnu razinu sUA od ≥5,0 mg/dl, postignutu nakon 3 tjedna liječenja samo s febuksostatom.
If this happens, keep taking Zurampic and talk to your doctor or pharmacist. 
Ako do toga dođe, nastavite uzimati Zurampic i obratite se svom liječniku ili ljekarniku.
Common - may affect up to 1 in 10 people - flu (influenza), - headache, - increase in the amount of creatinine in your blood -shown in tests, - heartburn(acid reflux). 
Često - mogu se javiti u do 1 na 10 osoba - gripa, - glavobolja, - povećanje količine kreatinina u krvi -vidljivou pretragama, - žgaravica (vraćanje kiseline).
The target serum uric acid level is less than 6 mg/dL (360 µmol/L). 
Ciljna razina mokraćne kiseline u serumu je manje od 6 mg/dl (360 µmol/l).
Lesinurad also inhibits OAT4, a uric acid transporter involved in diuretic-induced hyperuricaemia. 
Lesinurad također inhibira OAT4, transporter mokraćne kiseline uključen u hiperuricemiju uzrokovanu diuretikom.
Zurampic should not be administered with inhibitors of mEH. 
Zurampic se ne smije primjenjivati istodobno s inhibitorima mEH.
- the other ingredients are: - tablet core: hypromellose, microcrystalline cellulose, lactose monohydrate (see section 2), 
- drugi sastojci su: - jezgra tablete:hipromeloza, mikrokristalična celuloza, laktoza hidrat(vidjeti dio2), krospovidon,
Therefore, it is recommended that patients are monitored for reduced efficacy of CYP2B6 substrates (e.g. bupropion, efavirenz) when co-administered with Zurampic. 
Prema tome, preporučuje se pratiti bolesnike zbog smanjene djelotvornosti supstrata CYP2B6 (npr. bupropion, efavirenz) prilikom istodobne primjene s lijekom Zurampic.
In rats, there was no effect on mating or fertility with lesinurad (see section 5.3). 
U štakora, primjena lesinurada nije imala učinak na parenje ili plodnost (vidjeti dio 5.3).
In vivo, lesinurad is neither an inhibitor nor an inducer of CYP2C9 and 2C8, but a mild to moderate inducer of CYP3A. 
In vivo, lesinurad nije ni inhibitor ni induktor CYP2C9 i 2C8, ali je blagi do umjereni induktor CYP3A.
Since the incidence of severe renal-related adverse events was increased with the monotherapy as compared to the combination therapy with a xanthine oxidase inhibitor, Zurampic should not be used as monotherapy (see sections 4.2 and 5.1). 
S obzirom da je incidencija teških nuspojava povezanih s bubrezima bila povećana tijekom monoterapije, u usporedbi s kombiniranom terapijom s inhibitorom ksantin oksidaze, Zurampic se ne smije primjenjivati kao monoterapija (vidjeti dijelove 4.2 i 5.1).
Zurampic must be taken together with allopurinol or febuxostat, which are medicines called ‘xanthine oxidase inhibitors' and are also used to treat gout by lowering the amount of uric acid in your blood. 
Zurampic se mora primjenjivati zajedno s alopurinolom ili febuksostatom, lijekovima koji se nazivaju „inhibitori ksantin oksidaze“ i također se primjenjuju za liječenje gihta tako što smanjuju količinu mokraćne kiseline u Vašoj krvi.